background

Reshaping Hypertension
with the MobiusHD® System

Now enrolling in the CALM-2 clinical study
for patients with poorly controlled hypertension

See if you qualify

CAUTION: investigational device. Limited by United States law to investigational use.

background

Hypertension impacts 1 billion people worldwide and the clinical consequences are devastating1,2,3

When your blood pressure is high:

 
You are 4x more likely to die from a stroke
You are 3x more likely to die from heart disease
of people who have a first heart attack...
of people who have a first stroke...
of people with chronic heart failure...
 

Have high blood pressure

 
Only about half
of people with high blood pressure have their condition under control
background

EVBA: EndoVascular Baroreflex Amplification

background

Mobius HD® System

The MobiusHD® System is the only hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure.

CAUTION: investigational device. Limited by United States law to investigational use.

background

AMPLIFY

Reshaping of carotid sinus amplifies baroreceptor signaling to the brain

REDUCE

Significant blood pressure reduction demonstrated in multiple clinical studies4

LONG LASTING

Durable safety and efficacy at two-years4

NON-SURGICAL

Minimally invasive access using endovascular techniques

background

Clinical Trials

  • CALM-FIM

    CALM-FIM was a prospective, first-in-human, open-label study done at six sites in Europe. The MobiusHD system was studied in patients with an office systolic blood pressure ≥160 mmHg despite taking at least three antihypertensive agents, including a diuretic.

    Results showed a significant decrease in mean ambulatory blood pressure in 73% of patients at 24 hours and blood pressure reduction of 21/12 mmHg at six months, as compared to baseline4.

      Publication can be found here.

  • CALM-2

    The MobiusHD System is being studied in the CALM-2 clinical trial in patients with resistant hypertension who remain uncontrolled despite pharmacologic treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy.

    The CALM-2 clinical trial is currently enrolling at select medical centers in the United States and Europe. For more information visit www.calm2study.com

    See if you qualify
background

About Vascular Dynamics

Vascular Dynamics Inc. is pioneering endovascular baroreflex amplification (EVBA) to advance the treatment of hypertension to bring a better quality of life to patients who are resistant to conventional treatments.

The MobiusHD System targets the natural baroreceptor response in the carotid sinus with a minimally invasive procedure and is designed to stimulate vasodilation, reduce heart rate and modulate kidney response, thereby decreasing blood pressure.

The MobiusHD system has received a CE mark and has been accepted to participate in the FDA’s Expedited Access Pathway (EAP) program. The MobiusHD System is investigational in the United States.

View Patents

CAUTION: investigational device. Limited by United States law to investigational use.

Leadership

background

Contact

Address:
2134 Old Middlefield Way, Suite J
Mountain View, California 94043 USA

P: +1.650.963.9370
E: info@vasculardynamics.com

©2018 Vascular Dynamics, Inc. All rights reserved.  |  Reshaping Hypertension is a trademark of Vascular Dynamics, Inc. MobiusHD is a registered trademark of Vascular Dynamics, Inc.